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We evaluated the impact of human leukocyte antigen (HLA) disparity (immunogenicity; IM) on
long-term kidney allograft survival. The IM was quantified based on physicochemical
properties of the polymorphic linear donor/recipient HLA amino acids (the Cambridge
algorithm) as a hydrophobic, electrostatic, amino acid mismatch scores (HMS\AMS\EMS)
or eplet mismatch (EpMM) load. High-resolution HLA-A/B/DRB1/DQB1 types were imputed
to calculate HMS for primary/re-transplant recipients of deceased donor transplants. The
multiple Cox regression showed the association of HMS with graft survival and other
confounders. The HMS integer 0–10 scale showed the most survival benefit between HMS
0 and 3. The Kaplan–Meier analysis showed that: the HMS=0 group had 18.1-year median
graft survival, a 5-year benefit over HMS>0 group; HMS ≤ 3.0 had 16.7-year graft survival, a
3.8-year better thanHMS>3.0 group; and, HMS ≤ 7.8 had 14.3-year grafts survival, a 1.8-year
improvement over HMS>7.8 group. Stratification based on EMS, AMS or EpMM produced
similar results. Additionally, the importance of HLA-DR with/without -DQ IM for graft survival
was shown. In our simulation of 1,000 random donor/recipient pairs, 75% with HMS>3.0
were re-matched into HMS ≤ 3.0 and the remaining 25% into HMS≥7.8: after re-matching, the
13.5 years graft survival would increase to 16.3 years. This approach matches donors to
recipients with low/medium IM donors thus preventing transplants with high IM donors.
Keywords: kidney transplantation, kidney allocation, transplant survival, human leukocyte antigen (HLA), HLA
mismatch, immunogenicity
INTRODUCTION
The impact of the human leukocyte antigen (HLA)-A/B/DR mismatch (MM) on kidney allograft
survival has been a subject of extensive research (1–4). While some researchers argue that the role of
HLA matching is exaggerated (5), the consensus is that HLA compatibility between a donor and a
recipient (HLA immunogenicity) affects long-term kidney outcomes (6). Fully matched (0-HLA-A/
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B/DR MM) transplants consistently demonstrated the best
kidney allograft survival, and fully mismatched (6-HLA-A/B/
DR MM) transplant had the worst outcomes, whereas the
remaining 1-, 2-, 3-, 4-, and 5-HLA MM groups had
incrementally distributed survival between 0- and 6-HLA MM
cohorts (1, 2). The graft half-life for kidney transplant from
deceased donors was reported as 9.3 years in 2005 and 9.9 years
in 2010 (7). Kaplan–Meier and Cox models showed that HLA
disparity and multiple other factors may affect kidney allograft
survivals (8).
In the U.S., most of ABO-compatible kidney transplants are
performed without HLA matching, with the exception for few
special programs (5, 9, 10). Between 2012 and 2016, only 16.4%
of patients received “well-matched” deceased donor kidney
transplants at 0-, 1- or 2-HLA MM. The remaining 83.6% of
kidney transplants had 3-, 4-, 5-, and 6-HLA MM and therefore
should be considered as poorly matched (11). Existing
government programs prioritize 0-HLA MM kidney
transplants for sensitized patients (12). In particular, the 0-
MM benefits patients with HLA-A/-B/-DR matched donors
who have a panel reactive antibody (PRA)>20%. From
December 2014, the kidney allocation system (KAS) targets
patients with a PRA≥98% and patients waiting ≥10 years on
dialysis. The remaining procured kidneys are allocated according
to UNOS policies that rarely grant points for HLA matches.
Indeed, it is logistically impossible to match HLA for every
transplant, and thus less than 10% of patients receive 0-HLA
MM kidney transplants every year (13).
Not all HLA mismatches are equal, however. The idea of
weakly immunogenic HLA mismatches has been used for 30
years in the Acceptable Mismatch program, benefiting over 1,000
very highly sensitized patients (14). Increasing availability of
high-resolution HLA typing encourages analysis of molecular
disparities in HLA for quantifying HLA immunogenicity beyond
antigenic mismatches. One of resulting concepts was
HLAMatchmaker for finding immunogenic HLA eplets (15).
Eplets represent polymorphic HLA amino acids recognized by T
and B cells (15). Alternatively, the Cambridge algorithm is based
on the physicochemical properties of polymorphic HLA amino
acid residues (16, 17). This algorithm quantifies HLA disparities
based on its hydrophobic (HMS), electrostatic (EMS) and amino
acid (AMS) properties. These physicochemical-based scores
correlated with eplet MM load numbers, as well as the quality
of alloantibody response and kidney allograft rejection (18, 19),
or graft-versus-host disease (GVHD)-free survival after bone
marrow transplantation (20). Conceptually, an association was
recently shown between donor three-dimensional EMS value
and the generation of specific antibody response (21). While
other algorithms for HLA IM quantitation exist, the practical and
clinically-relevant IM calculation needs to be developed (22).
With decreasing costs and shortening testing times, the 4-
digit high-resolution HLA typing is an upcoming revolution in
transplantation. Recently published rapid testing techniques may
soon make it feasible for deceased donor transplants (23).
Implementing 4-digit HLA typing has a potential to better
avoid unacceptable antigens for sensitized patients. Herein, we
explored an additional power of 4-digit HLA typing to provide a
benefit of weakly immunogenic transplants and thus improve the
long-term graft survival for all patients.
We examined the potential of 4-digit HLAs for finding weakly
immunogenic donors. As opposed to the traditional seven
integer 0–6-HLA mismatch (MM) system, a continuous
physicochemical IM scale based on 4-digit HLA types in HLA-
A/B/DRB1/DQB1 loci converts antigen mismatch categories into
numerical values on a continuous scale. We propose that a
continuous IM scale offers greater freedom in finding weakly
immunogenic transplants, ultimately allowing improvement of
kidney allograft survival. Using the Scientific Registry of
Transplant Recipients (SRTR) data, we calculated the HMS,
EMS, and AMS by the Cambridge algorithm as well as eplet
MM (EpMM) by the HLAMatchmaker for class I (HLA-A/B)
and class II (HLA-DRB1/DQB1) HLAs to correlate their values
with the long-term kidney allograft survival. We used the Cox
regression model to confirm an association between HMS, EMS,
AMS, EpMM scores, graft survival, and multiple covariates.
Furthermore, we created a simulated allocation model to check
whether low/medium immunogenic ABO-compatible donors
may be identified for all recipients in comparison to a small




The Scientific Registry of Transplant Recipients (SRTR) database
was the source of transplant records between 01/01/2000 and 09/04/
2016 (Figure 1). Out of all 132,515 recipients of deceased donors,
high-resolution HLAs were imputed for 78,864 donor/recipient
pairs based on available race and HLA-A/B/DR 2-digit antigens;
this cohort included 29,852 pairs with HLA-A/B/DRB1/DQB1
types available. The 78,864-cohort had 65,615 patients with
primary and 13,249 patients with repeat transplants.
Disclaimer. The SRTR data include all donors, wait-list
candidates, and transplant recipients submitted by the
members of the Organ Procurement and Transplantation
Network (OPTN). The Health Resources and Services
Administration (HRSA) is the U.S. Department of Health and
Human Services providing an oversight to the activities of the
OPTN and SRTR contractors.
Imputation of High-Resolution HLA Types
and Calculation of Immunogenicity
The HaploStats algorithm of the NMDP bioinformatics group
was used to impute high-resolution HLA-A/B/DRB1/DQB1 to
assign the possible corresponding high-resolution HLA types
(24, 25). The frequency of HLA haplotypes was calculated based
on the distribution of race in the 2011 NMDP full database (26):
the most frequent high-resolution haplotype was assigned to the
individual. The high likelihood of imputed of HLA alleles was
recently demonstrated on a 5,000 cohort of patients in the U.K,
Bekbolsynov et al. HLA Immunogenicity for Improved Allocation
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namely 91% for HLA-A, 88% for -B, 67% for -DR, and 95% for
-DQ, producing an average of 85% (27).
The physicochemical IM for each donor-recipient pair was
calculated using the Cambridge algorithm, which assigns a score
to each amino acid mismatch between donor and recipient HLA
(16, 17). HLA-A/B/DRB1 or HLA-A/B/DR/DQB1 was used to
quantitate the hydrophobic (HMS), electrostatic (EMS), and amino
acid (AMS) mismatch scores: IM scores for each transplant were
calculated as averages for class I (HLA-A/B) and class II (DR ± DQ)
loci. That way, 50% of the IM score was contributed by DR alone or
DR/DQ combination, as was suggested before (28).
In addition, eplet mismatch (EpMM) scores were calculated
in version 3.1 of HLAMatchmaker. Sums of antibody-verified
eplet loads in HLA-DRB1 and HLA-A/B loci were used as
EpMM values in the sub-cohort of 47,241 patients.
To verify the accuracy of high-resolution HLA types
imputation, a cohort of transplant candidates from Queen
Elizabeth II Health Sciences Centre, Halifax, Canada (n =
1,095) typed to 2-field, P-group resolution at HLA-A/B/C/
DRB1/DQB1 loci using a combination of sequence based
typing and extended region SSO methods was used as a
reference. Imputed and known high-resolution HLA types and
immunogenicity values calculated based on them were then
statistically evaluated.
Statistical Analyses
Graft loss for death-censored graft survival analyses was defined
as reported graft failure, resumption of dialysis, re-transplant, or
listing for re-transplant. Deaths with functioning graft were
censored. Graft half-lives or median survival (time points
where 50% of transplants survived) was established using
Kaplan–Meier estimates. When follow-up time was shorter
than the graft half-life, a linear survival curve was projected
starting from day 4,000 post-transplant.
Four immunogenicity cutoffs were applied to define
immunological risk categories that were tested in Kaplan–
Meier survival estimates (see Table 3). Within the HMS scale,
the “perfect allelic match” was HMS=0, the “predictive
threshold” was HMS=1.8 [established by maximally selected
rank statistics method, (29)], the “weakly immunogenic”
threshold was HMS=3.0 (equal to average HMS in patients
with 0-/1-HLA MM) and the “median” threshold was
HMS=7.8. Analogous thresholds were defined individually for
EMS, AMS and EpMM scales. The same approach was used for
HLA MM scale.
Multiple Cox regression models analyzed the association of
graft loss risk with immunogenicity and other confounders
(Table 1). All data analyses were performed in SAS 9.4 (SAS
Institute Inc., Cary, NC) and R (R Foundation for Statistical
Computing, Vienna, Austria) programs.
Building the Proportional Hazards Model
A semi-parametric multiple Cox proportional hazards model
estimated the death-censored graft failure as a function of HLA
immunogenicity and other confounders. Univariate regression
models identified 16 confounders that were significantly
associated with death-censored graft survival (Table 1), using a
previously described approach (30). With the exception for pre-
transplant dialysis and recipient education level, all confounders
had less than 10% of missing values; records with missing values
were excluded.
All selected variables were tested for the proportional hazard
assumption using ASSESS statement of PHREG procedure in
SAS. This statement simulated 1,000 possible components vs.
follow-up time plots (31, 32). The Kolmogorov-type supremum
test was performed to establish the deviation from the simulated
plots of score process components and time, indicating a possible
violation of proportionality assumption. Additional verification
FIGURE 1 | Background characteristics of patient groups represented in the study. The total population of 78,864 patients included 65,615 recipients with primary
kidney transplants and 13,249 with re-transplants. Further details are presented in Materials and Methods.
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was performed using Schoenfeld residuals and log-negative log
plots for each variable (not shown). Variables violating the
proportional hazard assumption were included in the Cox
model with time log transformation (33).
Simulated Allocation Model
We have designed a simulated allocation algorithm to test the
maximum number of donors that could be found for recipients
within a designated HMS threshold. When the HMS was greater
than the designated threshold, the pair was broken and
simulation re-run with other broken pairs until the number of
pairs under the designated HMS threshold stopped growing.
Thus, a maximum number of low IM pairs within a given
population was established. Four input populations (n =10, n =
100, n = 1,000, or n = 5,000) and five IM thresholds (HLA MM ≤
1 or HMS = 0, HMS ≤ 3.0, HMS ≤ 5.5 or HMS ≤ 7.8) were tested.
This procedure was repeated 10 times always with new pairs for
all except 5,000 pairs, which was run only once as re-matching
was prohibitively lengthy.
RESULTS
Patient Demographics and 4-Digit
HLA Imputation
A total of 78,864 kidney primary and re-transplants from the
SRTR were included into cohort. Baseline characteristics of the
cohort are presented in Table 1. There were 30,526 (38.7%)
female recipients and 48,338 (61.3%) male recipients with mean
age at transplant of 51.9 years; 13,553 patients died with a
functioning kidney. Among donors, 32,422 (41.1%) were
female 46,442 (58.9%) were male; their mean age was 38.4
years. Recipients were represented by mostly non-Hispanic
whites (46.2%), while 35.0% were black. Recipients who had at
least a high school education or less represented most of patients
(47.0%), whereas 40.8% of patients attended college. Most
patients (80.7%) were on hemodialysis prior transplantation.
To assure the accuracy of our analyses, the same imputation
from 2-digit to 4-digit HLA-A/B/DRB1/DQB1 types was performed
for the individuals typed at Queen Elizabeth II Health Sciences




Less than 18 8,399 10.7
18 to 34 23,256 29.5
35 to 49 24,073 30.5
50 to 64 20,278 25.7
65 and over 2,858 3.6
Recipient age
18 to 34 9,275 11.8
35 to 49 22,053 27.9
50 to 64 33,348 42.3































None, grade school or high school 37,073 47.0
Attended college, bachelors or post-college 32,207 40.8
Unknown 9,584 12.2
Recipient primary source of payment
Private insurance 31,976 40.5




Less than 24 hours 58,092 73.7
24 hours or more 15,508 19.7
Unknown 5,264 6.6
Waiting time
Less than 1 year 25,497 32.3
1 to 3 years 29,350 37.2
3 to 5 years 15,980 20.3
Over 5 years 8,037 10.2









Type I 2,482 3.2




No dialysis 15,219 19.3
Hemodialysis 45,586 57.8
Peritoneal Dialysis 8,345 10.6
Continuous Venous/Venous 739 0.9
Hemofiltration
Unknown 8,975 11.4
*PRED indicates the use of steroids or steroid-free regimen.
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Centre with high resolution at HLA-A/B/DRB1/DQB1 loci (n =
1,095). The imputed high-resolution was 96% identical in HLA-A
locus, 92% in -B locus, 73% in -DRB1 locus, and 85% in -DQB1
locus (Table 2). In addition, we used the above individuals in an
experiment to test the impact of imputedHLAs vs. real HLAs on the
accuracy of IM calculation in our analysis: 547 presumed donors
and 547 presumed recipients were used to calculate HMS/EMS/
AMS values. In paired t-test, there was no difference between HMS
(p = 0.31), EMS (p = 0.36), and AMS (p = 0.37) values of imputed
vs. real 4-digit HLA types. Thus, the HLA imputation had little, if
any, impact on this proof-of-concept results (Table 2).
Association of HLA Mismatch Levels
With HMS Immunogenicity Scores
Currently, the HLA IM between a donor and a recipient is
defined at 2-digit level as 0–6 HLA-A/B/DR MM. We
investigated the association of kidney allograft survival where
HLA IM was defined at 4-digit level by the Cambridge algorithm
(16, 17). The HMS, EMS, and AMS MM scores strongly
correlated based on intra-class correlation coefficient of 82.5%
(HMS/EMS linear regression at R2 = 0.90), as previously reported
(16). When HMS, EMS, and AMS values were plotted on the 0-
to 6-HLA MM scale, the 1- and 2-HLA MM groups had the
lowest whereas the 5- and 6-HLA MM groups had the highest
average HMS values (Figures 2A–C). However, while the low IM
scores were found predominantly among 0-, 1-, and 2-HLA MM
pairs, they were also present in 3-, 4-, 5- and 6-HLAMM groups.
The same was true for highly IM transplants, high HMS values
were found in the 1- to 6-HLA MM groups. Similar HMS
distribution patterns were in the primary and re-transplant
cohorts (not shown).
Multiple Cox Regression Analysis
A semi-parametric multiple Cox proportional hazard method
estimated the association of HMS values with other confounders
on the risk for graft failure. Selected confounders showed a
significant association with the death-censored graft survival in
univariate Cox regression models (Supplemental Table 1).
Those variables were then tested for the proportional hazard
assumption using ASSESS statement of PHREG procedure in
SAS (31, 32), and variables violating the proportional hazard
assumption were included with time log transformation (33). All
HLA MM, and HMS values were significantly associated with
graft loss. In conclusion, the HMS-measured IM had significant
association with the death-censored graft survival in multiple
regression models (Supplemental Table 2). In addition,
immunosuppression, induction therapy, PRA levels, and cold
ischemia time were associated with the risk of graft loss (p <
0.001; Supplemental Table 2).
Low Immunogenicity Scores in HLA-A/B/
DR Correlate With Better Kidney
Allograft Survival
Overall, our 78,864 cohort had a 10-year kidney transplant survival
of 62.3% with half-life of 13.5 years (Figure 3A). Traditional 0- to 6-
HLA MM plots showed an incremental decrease in death-censored
graft survival (Figure 3B): 0-MM had 71% 10-year survival with
half-life of 15.5 years, while 6-MM had only 57% 10-year survival
with graft half-life of 11.8 years (Figures 3A, B; Table 3). The same
pattern was for primary/re-transplant or just primary (not shown)
transplants, as was previously described (1, 2).
Our goal was to select an HMS threshold with the largest
number of patients producing graft survivals as in a 0-/1-HLA-
A/B/DR MM cohort. In particular, we stratified transplant
recipients into four immunological risk categories based on
HMS (EMS, AMS, or EpMM) thresholds and analyzed their
graft failure rates in Kaplan–Meier survival estimates. The HMS-
based thresholds were HMS=0 (perfect allelic match), HMS=1.8
(predictive threshold), HMS=3.0 (low IM threshold; equal to
mean HMS in 0-/1-HLA MM), and HMS=7.8 (median HMS
threshold). EMS, AMS, and EpMM-based thresholds were
defined similarly and their corresponding values (Table 3).
In detailed analysis, the perfect allelic match HMS=0 selected
4,899 patients with graft half-life of 18.1 years, gaining 5.0 years
over 13.1 years for the HMS>0 group (p < 0.001; Figure 3C;
Table 3). The predictive threshold based on the maximally-
selected statistics (29) calculated an HMS=1.8 as low-risk
predictor for the graft loss (p < 0.001; Figure 3D). The HMS ≤
1.8 group had 7,846 patients with 16.6-year graft half-life, a 3.6-
year improvement over 13.0 years in the HMS>1.8 group (p >
0.001; Figure 3D; Table 3). In another analysis, with the 0–10
HMS integer scale, the most gain for the graft survival was
observed in transplants with HMS up to 3.0. This HMS ≤ 3.0
threshold included 11,483 transplants with 16.7-year graft
survivals, a 3.8-year gain over 12.9-year in the HMS>3.0 group
(p < 0.001; Figure 3E; Table 3). Finally, the median HMS ≤ 7.8
TABLE 2 | Identity between the known and imputed high-resolution types in the 1,095 patients from Haifax (upper part) and similarity between physicochemical
immunogenicity levels calculated based on them (lower part).
Identity of imputed high-resolution HLA types to the laboratory results
HLA Locus A B DR DQ
% of Identical typing 96.1 92.7 73.8 85.3
Immunogenicity calculated based on real or imputed high-resolution HLA types
Immunogenicity measure HMS EMS AMS
Real Imputed Real Imputed Real Imputed
Mean 12.04 11.91 12.22 12.11 8.23 8.17
Paired t-test p-value 0.316 0.362 0.369
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cohort achieved 14.3-year survival, a 1.8-year better than 12.5
years for HMS>7.8 cohort (p < 0.001; Figure 3F; Table 3).
Notably, the transplants with HMS ≤ 1.8 and HMS ≤ 3.0 had
graft survival better or equal to that in the 0-/1-HLA MM cohort
(Figure 4); however, the number of patients in HMS ≤ 1.8 and
HMS ≤ 3.0 was significantly higher than in the 0-/1-HLA MM
cohort (Table 3). The EMS, AMS, and EpMM values showed
similar patterns with their own specific thresholds; EpMM
evaluation displayed comparable results (Table 3).
The Dominant Role of -DR With -DQ HMS
Values in Kidney Allograft Survival
Since donor class II -DR and -DQ mismatches proved to be very
important in kidney allograft survivals (19, 34–36), we examined
their impact at the same HMS thresholds. The 29,852 HLA-A/B/
DR/DQ cohort showed that recipients matched at -DR alone had
grafts surviving 15.3 years while those matched at -DQ alone 15.0
years (Table 4). The HMS=0 group matched at HLA-A/B/DR
exhibited an extra benefit from an additional matching at -DQ
with 18.4 years vs. 15.6-year survivals with mismatch at -DQ, an
almost 3.0-year benefit (Table 4); similar gains were produced by
-DQ matching at HMS ≤ 3.0 and HMS ≤ 7.8 (Table 4). The
importance of -DR over -DQ was shown when the entire cohort
was matched vs. mismatched at only -DR (Figure 5A) as well as
matched vs. mismatched at only -DQ (Figure 5B), as the benefit
of additional -DQ match in -DR matched transplants was not
statistically significant. Similar patterns were also displayed when
HMS ≤ 3.0 was calculated only for -DR or -DQ (Figures 5C, D).
However, patients with HMS matched at HLA-A/B/DR had an
extra benefit from an additional -DQ match (Table 4,
A B C
FIGURE 2 | The distribution of physicochemical HMS, EMS, and AMS mismatch (scores across the antigenic 0–6-HLA MM groups. Each dot represents 200
donor–recipient pairs; Panels (A) (HMS), (B) (EMS) and (C) (AMS) has 78,864 recipients of primary or repeat kidney allografts. More details in Materials and Methods.
TABLE 3 | Graft half-lives based on death-censored graft survival analyses using the different immunogenicity scales in the primary/re-transplants cohort.
Immunogenicity was calculated based on HLA-A/B/DR loci. Graft half-life values over 16.1 years were imputed as described in Materials and Methods section.
Immunogenicity Cutoff value Graft Half-Life, years (95% CI*) n
Below Cutoff Above Cutoff Below Cutoff Above Cutoff
0-6 MM scale**
Antigenic Match (MM = 0) 15.5 (15.1–NA) 13.4 (13.1–13.7) 5,971 72,208
Predictive Threshold (MM = 3) 15.1 (14.6–15.6) 13.0 (12.7–13.3) 19,826 58,353
Weakly Immunogenic (MM ≤ 1) 16.1 (15.1–NA) 13.3 (13.0–13.6) 6,723 71,456
Median (HLA MM = 4) 14.4 (14.1–14.9) 12.9 (12.3–13.2) 39,853 38,326
HLA-A/B/DR HMS scale
Allelic Match (HMS = 0) 18.1 (15.1–NA) 13.4 (13.1–13.7) 4,899 73,884
Predictive Threshold (HMS = 1.8) 17.0 (15.1–NA) 13.3 (13.3–13.0) 7,846 70,945
Weakly Immunogenic (HMS = 3.0) 16.7 (15.7–NA) 12.9 (9.8–13.8) 11,483 67,381
Median (HMS ≤ 7.8) 14.3 (14.0–14.6) 12.5 (12.2–13.0) 39,439 39,425
HLA-A/B/DR EMS scale
Allelic Match (EMS = 0) 17.1 (15.1–NA) 13.4 (13.1–13.7) 4,701 74,163
Predictive Threshold (EMS = 1.8) 16.2 (15.1–NA) 12.8 (12.4–13.2) 7,858 71,006
Weakly Immunogenic (EMS = 3.6) 16.7 (15.1–NA) 13.2 (12.9–13.6) 14,165 64,699
Median (EMS = 7.9) 14.4 (14.2–15.0) 12.8 (12.4–13.1) 39,226 39,638
HLA-A/B/DR AMS scale
Allelic Match (AMS = 0) 17.1 (15.1–NA) 13.4 (13.1–13.7) 4,899 73,965
Predictive Threshold (AMS = 2.5) 15.6 (15.1–NA) 13.2 (12.9–13.5) 9,782 69,082
Weakly Immunogenic (AMS = 2.3) 15.3 (15.0–NA) 13.1 (12.9–13.4) 9,712 69,647
Median (AMS = 5.8) 14.4 (14.1–14.8) 12.9 (12.4–13.2) 25,841 53,023
HLA-A/B/DR Antibody-Verified Eplet load scale
Allelic Match (EpMM = 0) 22.6 (NA–NA) 15.3 (15.0–15.6) 1,584 45,657
Predictive Threshold (EpMM = 2) 17.5 (NA–NA) 15.1 (14.9–15.6) 6,335 40,906
Weakly Immunogenic (EpMM = 1.7) 18.3 (NA–NA) 15.1 (14.9–15.6) 5,419 41,882
Median (EpMM = 5.5) 15.2 (14.4–16.1) 13.5 (13.2–13.8) 21,170 20,071
*NA in confidence intervals indicates the upper survival limit was too far in the future to be computed in PROC LIFETEST procedure.
**The total numbers of patients in HLA MM categories is 78,179, reflecting records with blank HLA MM variable values.
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Supplemental Figures 1A–C). This benefit was stronger from
-DR matching in transplants already matched by -DQ than vice
versa (Supplemental Figures 1D, E). Our conclusion is that the
-DRB1 locus plays the dominant role in the HMS values, but
additional matching at -DQB1 locus improves an overall
graft survival.
Simulated Matching to Generate the
Maximum Possible Number of Weakly-
Immunogenic Donor/Recipient Pairs
So far, only 6% of deceased donor transplants were fully matched
(11), while 83.6% of transplants had more than three HLA-A/B/DR
mismatches. The new kidney allocation policy by OPTN (Organ
Procurement and Transplantation Network) establishes a 250-mile
radius procurement regions for deceased kidney harvesting,
assigning in the order of ≈1,000 deceased kidneys per region (37).
We tested whether HMS thresholds could reshuffle donors to
recipients to maximize those with HMS ≤ 3.0, HMS ≤ 5.5, or
HMS ≤ 7.8 (Table 5). Random donor/recipient pair populations
were re-matched to form the maximum possible number of new
pairs that would have HMS or HLA MM value within the
designated IM threshold. ABO compatibility was or was not
enforced in simulated pairs. This approach re-matched up to 85%
of pairs under HMS ≤ 3.0 in the population of 5,000 input pairs
(Table 5). Furthermore, enforcing HMS ≤ 7.8 threshold produced
95% matches for 1,000 and 99% for 5,000 random pairs. Re-
matched weakly immunogenic donor/recipient pairs had recipient
ABO distribution similar to that in the general population
(Supplemental Table 3). Enforcing ABO matching produced
slightly lower percentages of donor/recipient pairs that could be
re-matched, though that difference was small in n = 1,000 and n =
5,000 trial sizes (Table 5). Remarkably, re-matching of 1,000 pairs to
obtain the largest number of 0-/1-HLA MM pairs produced only
12.5% ( ± 0.85%) matches (Table 5). Thus, a continuous IM scale
may find low IM donors for most patients and may exclude all
transplants with high IM donors (HMS>7.8).
DISCUSSION
The main message is that a continuous HLA IM scale finds low-





FIGURE 3 | The Kaplan–Meier death-censored graft survival as a function of
HLA immunogenicity in primary/re-transplant cohort (n = 78,865). Panel (A)
presents the unadjusted primary/re-transplant cohort; Panel (B) presents
patients stratified by 0–6-HLA mismatches; Panel (C) presents patients with
HMS=0 vs. patients with HMS>0; Panel (D) presents patients with HMS ≤ 1.8
vs. patients with HMS>1.8; Panel (E) presents patients with HMS ≤ 3.0 vs.
patients with HMS>3.0; and Panel (F) presents patients with HMS ≤ 7.8 vs.
HMS>7.8. More details in Materials and Methods.
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FIGURE 4 | The Kaplan–Meier death-censored graft survival in patients selected by different HMS thresholds compared to patients with combined 0-/1-HLA MM
selected from the primary/re-transplant cohort (n = 78,865). Patients with HMS=0 (A), patients with HMS≤ 1.8 (B), patients with HMS ≤ 3.0 (C), and patients with
HMS≤ 7.8 (D) were compared to the patients in the same cohort with 0-/1-HLA MM.
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report herein four main findings. First, the IM, calculated for
HLA-A/B/DR/DQ of each donor/recipient pair by the
Cambridge algorithm (HMS) correlated with long-term kidney
allograft survivals. Second, low IM donors were selected on a
flexible scale ranging from zero to median HMS values. Third,
the HMS ≤ 3.0 threshold had an excellent 16.7-year graft survival
with a 3.8-year benefit over HMS>3.0 transplants; the median
HMS ≤ 7.8 threshold had 14.2-year graft survival, a 2.8-year
benefit. Fourth, 75% of 1,000 random ABO-matched patients
were then re-matched with HMS ≤ 3.0 value and the remaining
25% with the medium HMS 3.0–7.8 value. Overall, such
approach in our cohort would increase the graft half-life from
13.5-years to 16.4 years. Thus, the high-resolution HLA typing
with the HMS-based matching could revolutionize the selection
of donors.
The 2-digit 0-HLAMM group with graft survival of 15.5 years
included the “real” 4-digit 0-HLA MM transplants (HMS = 0)
with superior graft survival of 18.1 years. Thus, only precise 4-
digit HLA matching produced “perfect” matches with superior
outcomes, otherwise achieved only by living related donors (38).
This was as equally impressive as 16.7-year graft half-life among
11,483 patients with HMS ≤ 3.0 selected from the 0- to 6-MM
cohort (Table 3). The median HMS ≤ 7.8 threshold had graft
survivals of 14.3 years and that should be the upper limit to avoid
high IM transplants (HMS > 7.8). The survival benefit in weakly
immunogenic transplants is excellent in recipients of kidneys
with full allelic match, but when HMS=0 patients were excluded
from HMS ≤ 3.0 cohort, the graft survival still was significantly
higher than in HMS>3.0 cohort (14.6 vs 12.9 years, not shown).
While HLA-DR was dominant in contributing to the HMS
TABLE 4 | HLA-class II immunogenicity and graft survival. Graft half-lives based on death-censored graft survival analyses with 0- to 2-HLA MM scale and the flexible
HMS scale in the primary/re-transplants cohort. Immunogenicity was calculated based on HLA- DRB1 and/or HLA-DQB1 loci.
HLA-DRB1 or -DQB1 N Graft half-life, years (95% CI) 95% CI*
HLA-DR MM = 0 15,014 15.3 15.1–NA
HLA-DQ MM = 0 5,775 15.0 14.3–NA
HLA-A/B/DR/DQ N Graft half-life, years (95% CI) 95% CI*
A/B/DR HMS = 0, -DQ MM = 0 1,864 19.2 NA–NA
A/B/DR HMS = 0, -DQ MM = 1 or 2 1,068 18.1 15.1–NA
A/B/DR HMS ≤ 3.0, -DQ MM = 0 2,773 18.4 15.0–NA
A/B/DR HMS ≤ 3.0, -DQ MM = 1 or 2 2,846 15.6 15.1–NA
A/B/DR HMS ≤ 7.8, -DQ MM = 0 4,538 15.3 14.6–NA
A/B/DR HMS ≤ 7.8, -DQ MM = 1 or 2 11,289 13.9 13.1–15.1
Matched by HLA-DRB1 N Graft half-life, years (95% CI) 95% CI*
HLA-DR MM = 0, HLA-DQ MM = 0 3,883 15.3 15.0–NA
HLA-DR MM = 0, HLA-DQ MM = 2 624 16.1 9.7–NA
Matched by HLA-DQB1 n Graft half-life, years (95% CI) 95% CI*
HLA-DQ MM = 0, HLA-DR MM = 0 3,883 15.3 15.0–NA
HLA-DQ MM = 0, HLA-DR MM = 2 457 12.7 13.9–NA
*NA in confidence intervals indicates the upper survival limit was too far in the future to be computed in PROC LIFETEST procedure.
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FIGURE 5 | The Kaplan–Meier death-censored graft survival as a function of class II (HLA-DR and –DQ) immunogenicity in primary/re-transplant cohorts (n =
78,865). Panels (A, B) present patients stratified by mismatches at 0-, 1- or 2-HLA-DR (A) or -DQ (B) antigens. Transplants from donors with split broad antigens
(for example, HLA-DR3 in donor and HLA-DR17 in recipient—this could be either a match or a mismatch) were excluded from the analysis; Panel (C) presents
patients stratified by HLA-DR HMS ≤ 3.0 vs. HLA-DR HMS>3.0, and Panel (D) presents patients stratified by HLA-DQ HMS ≤ 3.0 vs. HLA-DQ HMS>3.0.
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benefit, matching at -DQ locus further improved allograft
survival in patients with low HMS scores (Table 4); the -DQ
analysis was limited by 30% availability of this locus typing in the
SRTR database. Overall, we propose that the Cambridge
algorithm proffers a versatile way to identify low/medium IM
donors independent of 0-6 HLA matching: the best results were
produced by HMS matching at the combined HLA-A/B/DR/
DQ loci.
A continuous IM scale is versatile. In the retrospective cohort
of 78,864 recipients, there were 11% more pairs with HMS ≤ 1.8
than those with 0-/1-HLA MM. Similarly, there were 35% more
pairs with HMS ≤ 3.0 than those with 0-/1-HLA MM. Given the
median graft survival in HMS ≤ 1.8 and HMS ≤ 3.0 groups was
comparable to that in the 0-/1-HLA MM group (Table 3), it is
easy to see that substantially better survival results could be
produced if more effort was put in finding weakly immunogenic
donors on a continuous IM scale. Exploring this insight, our
simulation found that 75% of 1,000 random pairs could be re-
matched with low (HMS ≤ 3.0) and remaining 25% with medium
(HMS 3.0–7.8) IM donors (Table 5). This would increase an
average graft survival by 21% from 13.5 years to 16.4 years
producing extra 224,762 kidney life years in 78,864 patients.
While we did take into consideration ABO compatibility,
unacceptable HLA antigens data was not available in the SRTR
database. Still, HMS alone and ABO blood groups/HMS re-
matching simulation provided a proof of concept: a random 10
to 5,000 pool of donor/recipient contain sufficiently diverse HLA
haplotypes to accommodate most if not all recipients with weakly
immunogenic grafts. We plan to quantify benefits using real-life
simulation conditions.
The proportional hazard regression already examined the
impact of HLA on graft survival with multiple covariates (2).
This multifactorial analysis provided tools for addressing
assumptions violations in the Cox model. Proportional hazard
distribution is one of the most important prerequisites in a
model validation (39, 40). Williams and his colleagues did not
find substantial deviations from the proportionality in their
research cohorts (2). Our data demonstrated significant non-
proportionality with most confounders, prompting our use of
time log transformation to rectify our model (33). It is possible
that the strict definition of proportionality could have
contributed to the difference. Despite this disparity, both Cox
analyses revealed that immunosuppression and induction
therapy had the highest impact (p < 0.001) on the IM-
dependent graft survival (2). Thus, immunosuppression and
induction covariates are affecting the HLA-based matching of
donors and recipients.
While imputation is not recommended for clinical decision
making (39), it is an invaluable tool for research. We have
developed an algorithm for fast imputation of high-resolution
HLA types on the HaploStats server (26). The proportion of HLA
alleles imputed with high likelihood was shown on 5,000
volunteers with 91% accuracy for HLA-A, 88% for -B, 67% for
-DRB1, and 95% for -DQB1 (an average of 85%) in previously
published research (27). Our analysis of 1,095 individuals
produced better results: the imputed/real high-resolution was
96% precise for HLA-A locus, 92% for -B locus, 73% for -DRB1
locus, and 85% for -DQB1 locus (Table 2). Future clinical
application needs bona fide 4-digit HLA typing rather than
imputed HLA identification.
The half-life of kidney grafts from deceased donors has
slightly improved from 7.4 years in 1994 to 9.8 years in 2008
(11). An independent 20-year study confirmed graft half-life of
9.3 years in 2015 (41). The 2-year improvement can be attributed
to better induction and immunosuppression therapy in almost
all recipients (42, 43). In the U.S., HLA matching is not done
because of the logistic complexity of the 0- to 6-HLA scale and
the desire to avoid disadvantaging minority patients. The
sensitization of patients further complicates selection of donors
(44–46). Our approach may help avoid unacceptable HLA alleles
when finding low IM donors.
Analysis of donor eplets, based on 4-digit HLAs, became
necessary to overcome an increasing number of new HLA alleles
(47). In fact, one very immunogenic eplet may be present on
multiple HLA molecules requiring their avoidance in donor
selection. The low HLA eplet mismatch (EpMM) load has been
considered as an extension of 2-digit HLA antigens in improving
donor choice, especially for children (48). Indeed, modified
TABLE 5 | Simulation analyses to re-match 10, 100, 1,000 or 5,000 donor/recipeint pairs with HMS = 0, HMS ≤ 3.0, ≤ 5.5, or ≤ 7.8.
Immunogenicity threshold ABO-matched Percent of re-matched pairs
n* = 10 n = 100 n = 1,000 n = 5,000
HMS = 0 No 1.00 6.90 16.10 23.53
Yes 2.00 6.30 14.01 22.05
HMS ≤ 3.0 No 15.91 44.00 72.98 84.85
Yes 7.00 32.60 63.61 79.07
HMS ≤ 5.5 No 47.00 71.40 88.00 93.20
Yes 26.00 60.70 83.10 89.96
HMS ≤ 7.8 No 58.00 81.60 95.33 98.72
Yes 46.00 73.60 90.32 96.26
HLA MM ≤ 1 No 1.00 3.20 14.49 ND**
Simulation program removes all donor-recipient pairs that are ABO-incompatible or have HMSgreater than the indicated thresholds and rearranges the pairs to achieve the maximumnumber of
pairs with HMS = 0, ≥ 3.0, ≥ 5.5, or ≥ 7.8, or HLA MM ≤ 1. The experiment with 1,000 pairs was repeated 10 times, whereas the experiment with 5,000 pairs was repeated once.
*n – population of donor/recipients pair size.
**ND – not done.
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Poisson regression showed that the EpMM load was an effective
tool in the risk assessment. In other work, EpMM values were
correlated with AMS and EMS scores (R2 = 0.85–0.96) in de novo
donor-specific antibody (dnDSA) production (19). Furthermore,
all three methods (EpMM, EMS, and AMS) correlated with
dnDSA following adjustment of variables such as recipient age,
immunosuppression, and non-compliance. Overall, the authors
suggested to use the easiest method as similar results were
produced by each method. We argue about the use of HMS,
EMS or AMS values. However, we also recognize the qualitative
differences among antibody-verified eplets as more or less
immunogenic, as others showed (47, 49, 50). Thus, we believe
that future approach should combine the HMS threshold with
antibody-verified EpMM analysis for the best pre-transplant
risk assessment.
In summary, we propose to prioritize low IM donors by
utilizing HMS-based selection instead of the rigid 0–6-HLA
system. Relying on physicochemical properties provides flexibility
and may accommodate all or almost all recipients. The application
of the HMS system for all deceased donor kidney transplants in
United States should significantly increase graft survivals.
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